NZ337056A - A 24 kD protein specific for binding to HCV epitotes which can be used for diagnosis and treatment of HCV related diseases
- Google Patents
A 24 kD protein specific for binding to HCV epitotes which can be used for diagnosis and treatment of HCV related diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9517926.3Aexternal-prioritypatent/GB9517926D0/en
Application filed by Chiron SfiledCriticalChiron S
Publication of NZ337056ApublicationCriticalpatent/NZ337056A/en
A use of a protein having a molecular weight of 24kD and capable of specifically binding to a protein of hepatitis C virus for treating HCV infection. The method of preparing the protein is characterised by: 1. Culturing plasma cells exhibiting binding to a HCV protein and purifying the protein from the preparation of the cells; 2. The cells are selected and cloned to provide for overexpression of the protein; 3. Subjecting the preparation to ammonium sulphate precipitation to ammonium sulphate at less than 33% saturation and retaining the supernatant; 4. Subjecting the supernatant to an ammonium sulphate precipitation (33 and 50%) purification step and retaining the precipitate; 5. Resuspending the precipitate and subjecting it to hydrophobic interaction chromatography. Figure 1 is a schematic diagram describing an assay in which HCV receptor-binding ligands bind to receptors on HCV receptor target cells and are measured by first binding a labeled anti-rabbit IgG-FITC F(ab') fragment prior to cell separation by FACScan analysis.
NZ337056A1995-09-011999-08-04A 24 kD protein specific for binding to HCV epitotes which can be used for diagnosis and treatment of HCV related diseases
NZ337056A
(en)
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2)
Process for the preparation of an interferon-induced human protein in pure form monoclonal antibodies thereto and test kits containing these antibodies